Finding better ways to predict how cancer treatments will work for patients
Official title: Statistical Methods for Identification and Evaluation of Predictive Biomarkers in Cancer
Funded at University of Kentucky · NIH-10866982 · Data updated 2026-11-12
This study is looking for ways to improve cancer treatments by finding new markers that can help doctors figure out which patients will benefit the most from specific therapies, and if you join, your information could help shape better treatment options for everyone.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | July 4, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $388,673 |
| NIH project number | 1R21CA284179-01A1 |
| Project ID | NIH-10866982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with relapsed or refractory cancer who are undergoing treatment with targeted therapies.
✕Less likely to help
Patients with early-stage cancer or those not receiving targeted therapies may not benefit from this research.
What this research studies
This research focuses on improving cancer treatment outcomes by identifying new predictive biomarkers that can help determine which patients are most likely to benefit from targeted therapies. By analyzing data from non-randomized phase II clinical trials, the study aims to evaluate treatment efficacy using progression-free survival (PFS) as a key endpoint. This approach will help stratify patients into subgroups based on their likelihood of experiencing favorable or unfavorable treatment effects, ultimately guiding more effective clinical trials and drug development. Patients may have the opportunity to contribute to this important work by providing data that could lead to better treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more personalized cancer treatments, improving outcomes for patients with relapsed or refractory cancer.
How similar studies have gone: Previous research has shown promise in using predictive biomarkers to enhance treatment outcomes in cancer, indicating that this approach has potential for success.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Chen, Li — University of Kentucky
- Study coordinator: Chen, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.